Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.

Launched by COORDINACIÓN DE INVESTIGACIÓN EN SALUD, MEXICO · Mar 31, 2022

Keywords

ClinConnect Summary

This clinical trial is studying two different schedules for radiation therapy in women with early-stage breast cancer, specifically those with ductal carcinoma in situ (DCIS) or invasive breast cancer. The trial compares a shorter 1-week radiation treatment plan to the standard 3.1-week schedule to see if both methods are equally effective in controlling the tumor and ensuring patient safety. The hope is that the shorter treatment may result in similar success rates while causing fewer side effects.

To participate in this trial, women aged 18 and older who have been diagnosed with DCIS or invasive breast cancer, and have undergone breast-conserving surgery, may be eligible. However, those with certain conditions, such as more advanced cancer or a history of radiation treatment, would not qualify. Participants can expect to receive either the shorter or the standard radiation treatment, and their progress will be monitored to evaluate the outcomes. This trial is currently recruiting patients, aiming to provide valuable insights into how radiation therapy can be optimized for better patient experiences.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed by histopathological report of ductal carcinoma in situ (DCIS) or invasive breast carcinoma.
• • Treated with breast-conserving surgery and stage pT1-2 pN0 M0.
• • Over 18 years.
• • Patients who sign informed consent for research study.
• Exclusion Criteria:
• • Positive nodes.
• • Clinical or pathological stage T3-T4.
• • History of previous irradiation.
• • Postoperative positive margin.